CO2018003971A2 - Suspensión acuosa para administración oral y método para su preparación - Google Patents

Suspensión acuosa para administración oral y método para su preparación

Info

Publication number
CO2018003971A2
CO2018003971A2 CONC2018/0003971A CO2018003971A CO2018003971A2 CO 2018003971 A2 CO2018003971 A2 CO 2018003971A2 CO 2018003971 A CO2018003971 A CO 2018003971A CO 2018003971 A2 CO2018003971 A2 CO 2018003971A2
Authority
CO
Colombia
Prior art keywords
oral administration
preparation
aqueous suspension
givinostat
oral
Prior art date
Application number
CONC2018/0003971A
Other languages
English (en)
Inventor
Giuseppe Colombo
Roberta Artico
Paolo Mascagni
Maria Valmen Monzani
Silvia Puccianti
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of CO2018003971A2 publication Critical patent/CO2018003971A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)

Abstract

RESUMEN Formulaciones líquidas orales física y químicamente estables de Givinostat (Dietil-[6-(4-hidroxicarbamoil-fenilcarboniloxietil)-naftalen-2-il-metil]-cloruro amónico) junto con métodos para la preparación de las mismas. Tales formulaciones orales son en forma de suspensiones acuosas y contienen Givinostat y/o sales aceptables para uso farmacéutico y/o derivadas de las mismas, por lo menos un agente humectante y/o por lo menos un agente que imparte densidad. Son adecuadas para la administración oral para la acción terapéutica sistémica.
CONC2018/0003971A 2015-11-03 2018-04-13 Suspensión acuosa para administración oral y método para su preparación CO2018003971A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITUB2015A005193A ITUB20155193A1 (it) 2015-11-03 2015-11-03 Sospensioni orali di Givinostat fisicamente e chimicamente stabili
PCT/IB2016/056496 WO2017077436A1 (en) 2015-11-03 2016-10-28 Physically and chemically stable oral suspensions of givinostat

Publications (1)

Publication Number Publication Date
CO2018003971A2 true CO2018003971A2 (es) 2018-07-19

Family

ID=55410062

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0003971A CO2018003971A2 (es) 2015-11-03 2018-04-13 Suspensión acuosa para administración oral y método para su preparación

Country Status (30)

Country Link
US (1) US10688047B2 (es)
EP (1) EP3370697B1 (es)
JP (1) JP6800970B2 (es)
KR (1) KR102603894B1 (es)
CN (2) CN113368044B (es)
AR (1) AR106559A1 (es)
AU (1) AU2016349169B2 (es)
BR (2) BR112018008870A8 (es)
CA (1) CA3002755C (es)
CL (1) CL2018001151A1 (es)
CO (1) CO2018003971A2 (es)
CY (1) CY1124092T1 (es)
DK (1) DK3370697T3 (es)
ES (1) ES2870201T3 (es)
HK (1) HK1254811A1 (es)
HR (1) HRP20210747T1 (es)
HU (1) HUE054123T2 (es)
IL (1) IL258608B (es)
IT (1) ITUB20155193A1 (es)
LT (1) LT3370697T (es)
MX (1) MX2018004505A (es)
NZ (1) NZ741467A (es)
PE (1) PE20181369A1 (es)
PL (1) PL3370697T3 (es)
PT (1) PT3370697T (es)
RS (1) RS61694B1 (es)
RU (1) RU2721396C2 (es)
SI (1) SI3370697T1 (es)
TW (1) TWI727983B (es)
WO (1) WO2017077436A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3976198A4 (en) 2019-05-31 2023-07-19 Viracta Subsidiary, Inc. METHODS OF TREATMENT OF VIRAL ASSOCIATED CANCER WITH HISTONE DEACETYLASE INHIBITORS
WO2022088037A1 (zh) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Sirtinol在制备预防和治疗冠状病毒的药物中的应用
CN114306311A (zh) * 2022-01-14 2022-04-12 同济大学 组蛋白去乙酰化酶抑制剂在制备治疗心脏病的药物中的应用
CN116173003A (zh) * 2023-02-24 2023-05-30 山西医科大学 药物吉维司他在治疗阿尔茨海默病中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169150A (en) * 1975-11-12 1979-09-25 Teijin Limited Benzodiazepine derivatives and pharmaceutical compositions containing said derivatives
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP4975941B2 (ja) 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
KR20040073493A (ko) * 2001-12-20 2004-08-19 파마시아 코포레이션 경구 투여용 제약 현탁액
DE60320957D1 (en) 2002-03-13 2008-06-26 Janssen Pharmaceutica Nv Sulfonylderivate als histone-deacetylase-inhibitoren
ITMI20030063A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
BRPI0409227C1 (pt) 2003-04-07 2021-05-25 Axys Pharm Inc composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
PL1656348T4 (pl) 2003-08-20 2007-07-31 Pharmacyclics Inc Pochodne acetylenu jako inhibitory deacetylazy histonowej
ITMI20041347A1 (it) 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
EA010652B1 (ru) 2004-07-28 2008-10-30 Янссен Фармацевтика Н.В. Замещенные индолильные алкиламинопроизводные в качестве новых ингибиторов гистондеацетилазы
WO2006018814A2 (en) * 2004-08-16 2006-02-23 Ranbaxy Laboratories Limited Oral liquid suspensions of metaxalone
WO2007135362A2 (en) * 2006-05-19 2007-11-29 Norbrook Laboratories Limited Stable aqueous suspension having palatable taste
EP2061772A4 (en) 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
EP2493473A1 (en) * 2009-10-30 2012-09-05 Janssen Pharmaceutica NV Dosing regimen associated with long-acting injectable paliperidone esters
IT1397912B1 (it) * 2010-01-28 2013-02-04 Chemi Spa Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
WO2011113013A2 (en) * 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
TW201245115A (en) * 2011-01-24 2012-11-16 Chdi Foundation Inc Histone deacetylase inhibitors and compositions and methods of use thereof
MX349767B (es) * 2012-02-03 2017-08-11 Italfarmaco Spa Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil) -naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
EP2968080B1 (en) * 2013-03-12 2023-05-10 Synedgen, Inc. Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar
EP2968233A4 (en) 2013-03-14 2016-08-03 Chdi Foundation Inc HISTON DEACETYLASE HEMMER AND COMPOSITIONS AND METHOD FOR USE THEREOF
WO2015086738A2 (en) 2013-12-11 2015-06-18 Bionor Immuno As Hiv vaccine

Also Published As

Publication number Publication date
ITUB20155193A1 (it) 2017-05-03
TW201722401A (zh) 2017-07-01
JP6800970B2 (ja) 2020-12-16
CL2018001151A1 (es) 2018-12-07
IL258608A (en) 2018-06-28
CN108366956A (zh) 2018-08-03
LT3370697T (lt) 2021-06-10
JP2019501116A (ja) 2019-01-17
HUE054123T2 (hu) 2021-08-30
HRP20210747T1 (hr) 2021-06-25
KR102603894B1 (ko) 2023-11-20
RU2721396C2 (ru) 2020-05-19
US10688047B2 (en) 2020-06-23
AU2016349169A1 (en) 2018-05-17
CA3002755C (en) 2022-10-18
KR20180082468A (ko) 2018-07-18
RU2018120170A (ru) 2019-12-05
CN113368044A (zh) 2021-09-10
SI3370697T1 (sl) 2021-04-30
CN113368044B (zh) 2023-06-02
PL3370697T3 (pl) 2021-07-12
PE20181369A1 (es) 2018-08-27
PT3370697T (pt) 2021-04-06
TWI727983B (zh) 2021-05-21
BR112018008870A2 (pt) 2018-11-06
AR106559A1 (es) 2018-01-24
MX2018004505A (es) 2018-09-12
IL258608B (en) 2022-06-01
WO2017077436A1 (en) 2017-05-11
HK1254811A1 (zh) 2019-07-26
EP3370697B1 (en) 2021-02-17
BR112018008870A8 (pt) 2019-02-26
US20180311160A1 (en) 2018-11-01
AU2016349169B2 (en) 2021-11-11
CN108366956B (zh) 2021-09-10
EP3370697A1 (en) 2018-09-12
CA3002755A1 (en) 2017-05-11
BR122024001653A2 (pt) 2024-03-05
DK3370697T3 (da) 2021-04-26
CY1124092T1 (el) 2022-05-27
RS61694B1 (sr) 2021-05-31
ES2870201T3 (es) 2021-10-26
RU2018120170A3 (es) 2019-12-05
NZ741467A (en) 2021-07-30

Similar Documents

Publication Publication Date Title
CO2018003971A2 (es) Suspensión acuosa para administración oral y método para su preparación
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
CL2015002835A1 (es) Nuevos derivados de piridina
CO2019000643A2 (es) Formulaciones gastrorretentivas orales y usos de las mismas
SV2017005603A (es) Formulacion solida oral que contiene irinotecan y metodo de preparacion de la misma
AR106505A1 (es) Tratamiento de la oligo-ovulación relacionada con esteatosis hepática
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
MX364800B (es) Tilmicosina de accion prolongada mejorada y el uso de la misma en el tratamiento del complejo respiratorio bovino (crb) y en el periodo de la vaca seca.
IT201800001301A1 (it) Formulazioni in gel per la somministrazione orale di farmaci, in particolare nei pazienti disfagici
CL2018001590A1 (es) Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina.
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
AR104185A1 (es) Formulaciones farmacéuticas
HK1243327A1 (zh) 包含螺旋藻和棕櫚酰基乙醇酰胺和/或其鹽或藥用上可接受衍生物的組合及其製劑，用於預防和/或治療過度活化的組織病症
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
PH12018502139A1 (en) Phosphaplatin liquid formulations
IT201600122310A1 (it) Composizione per uso nella terapia di alterazioni dell'intestino
MA42480A (fr) Préparations pharmaceutiques de dabigatran sous forme de base libre
AR103267A1 (es) Método para preparación de liposomas que contienen un ingrediente farmacéutico activo
EA201692013A1 (ru) Новое применение n,n-бис-2-меркаптоэтил-изофталамида
UY36958A (es) Compuestos para administración intracelular
ES2975004T3 (es) Sistema y método para el uso de composición de injerto óseo de una sola dosis ya preparada predosificada y preenvasada en bolsa o cápsula de gelatina y método para producirla